Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.

Bagrodia A, Kaffenberger S, Winer A, Murray K, Vacchio M, Zheng J, Ostrovnaya I, Bochner BH, Dalbagni G, Cha EK, Coleman JA.

World J Urol. 2018 Jan 17. doi: 10.1007/s00345-018-2180-3. [Epub ahead of print]

PMID:
29344681
2.

The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.

Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, Shariat SF.

Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30840-0. doi: 10.1016/j.eururo.2017.09.030. [Epub ahead of print] Review.

PMID:
29122377
3.

Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.

Bagrodia A, Sukhu R, Winer AG, Levy E, Vacchio M, Lee B, Pietzak EJ, Donahue TF, Cha E, Iyer G, Sjoberg DD, Vickers AJ, Rosenberg JE, Bajorin DF, Dalbagni G, Bochner BH.

Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30232-X. doi: 10.1016/j.clgc.2017.07.022. [Epub ahead of print]

PMID:
28866245
4.

Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder.

Mally AD, Tin AL, Lee JK, Satasivam P, Cha EK, Donat SM, Herr HW, Bochner BH, Sjoberg DD, Dalbagni G.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30199-4. doi: 10.1016/j.clgc.2017.07.002. [Epub ahead of print]

PMID:
28802887
5.

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.

Isharwal S, Audenet F, Drill E, Pietzak EJ, Iyer G, Ostrovnaya I, Cha E, Donahue T, Arcila M, Jayakumaran G, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, Dalbagni G, Reuter VE, Bochner BH, Solit DB, Al-Ahmadie HA.

Eur Urol Focus. 2017 Aug 10. pii: S2405-4569(17)30189-X. doi: 10.1016/j.euf.2017.07.004. [Epub ahead of print]

PMID:
28802642
6.

The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.

Li Q, Assel M, Benfante NE, Pietzak EJ, Herr HW, Donat M, Cha EK, Donahue TF, Bochner BH, Dalbagni G.

Eur Urol Focus. 2017 Jun 27. pii: S2405-4569(17)30164-5. doi: 10.1016/j.euf.2017.06.013. [Epub ahead of print]

PMID:
28753857
7.

Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?

Audenet F, Retinger C, Chien C, Benfante NE, Bochner BH, Donat SM, Herr HW, Dalbagni G.

Urol Oncol. 2017 Oct;35(10):603.e1-603.e5. doi: 10.1016/j.urolonc.2017.06.042. Epub 2017 Jul 6.

PMID:
28689694
8.

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH.

Eur Urol. 2017 Dec;72(6):952-959. doi: 10.1016/j.eururo.2017.05.032. Epub 2017 Jun 3.

PMID:
28583311
9.

Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063).

Dalbagni G, Benfante N, Sjoberg DD, Bochner BH, Machele Donat S, Herr HW, Mc Coy AS, Fahrner AJ, Retinger C, Rosenberg JE, Bajorin DF.

Bladder Cancer. 2017 Apr 27;3(2):113-119. doi: 10.3233/BLC-170095.

10.

Two cases of spontaneous remission of non-parasitic chyluria.

Mendu DR, Sternlicht H, Ramanathan LV, Pessin MS, Fleisher M, Dalbagni G, Jaimes EA, Kaltsas A, Glezerman IG.

Clin Biochem. 2017 Oct;50(15):886-888. doi: 10.1016/j.clinbiochem.2017.05.002. Epub 2017 May 4.

PMID:
28478046
11.

Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence.

Li Q, Assel M, Benfante N, Pietzak E, Bagrodia A, Cha E, Dalbagni G, Coleman J.

J Urol. 2017 Sep;198(3):546-551. doi: 10.1016/j.juro.2017.03.120. Epub 2017 Mar 22.

PMID:
28342936
12.

Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.

Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD, Sankin AI, Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.

Urol Oncol. 2017 Apr;35(4):151.e9-151.e15. doi: 10.1016/j.urolonc.2016.11.002. Epub 2016 Dec 5.

PMID:
27932270
13.

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.

Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serretta V, Larré S, di Stasi S, Colombo R, Babjuk M, Malmström PU, Malats N, Irani J, Baniel J, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R.

Urol Oncol. 2016 Nov;34(11):484.e19-484.e25. doi: 10.1016/j.urolonc.2016.05.033. Epub 2016 Sep 14.

14.

Preoperative Nutritional Status and The Impact on Radical Cystectomy Recovery: An International Comparative Study.

Jensen BT, Dalbagni G, Borre M, Love-Retinger N.

Urol Nurs. 2016 May-Jun;36(3):133-40, 152.

PMID:
27501594
15.

Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution.

Murray KS, Zabor EC, Spaliviero M, Russo P, Bazzi WM, Musser JE, Ari Hakimi A, Bernstein ML, Dalbagni G, Coleman JA, Furberg H.

World J Urol. 2016 Dec;34(12):1667-1672. Epub 2016 Apr 22.

16.

A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor.

Anderson C, Weber R, Patel D, Lowrance W, Mellis A, Cookson M, Lang M, Barocas D, Chang S, Newberger E, Montgomery JS, Weizer AZ, Lee CT, Kava BR, Jackson M, Meraney A, Sjoberg D, Bochner B, Dalbagni G, Donat M, Herr H.

J Urol. 2016 Oct;196(4):1014-20. doi: 10.1016/j.juro.2016.03.151. Epub 2016 Apr 1.

17.

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.

Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, Desai NB, Zabor EC, Ostrovnaya I, Gopalan A, Chen YB, Fine SW, Tickoo SK, Gandhi A, Hreiki J, Viale A, Arcila ME, Dalbagni G, Rosenberg JE, Bochner BH, Bajorin DF, Berger MF, Reuter VE, Taylor BS, Solit DB.

Nat Genet. 2016 Apr;48(4):356-8. doi: 10.1038/ng.3503. Epub 2016 Feb 22.

18.

The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm.

Mano R, Vertosick EA, Hakimi AA, Sternberg IA, Sjoberg DD, Bernstein M, Dalbagni G, Coleman JA, Russo P.

Urol Oncol. 2016 May;34(5):239.e1-8. doi: 10.1016/j.urolonc.2015.12.001. Epub 2016 Jan 12.

19.

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

Bagrodia A, Cha EK, Sfakianos JP, Zabor EC, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA, Iyer G, Scott SN, Shah R, Ostrovnaya I, Lee B, Desai NB, Ren Q, Rosenberg JE, Dalbagni G, Bajorin DF, Reuter VE, Berger MF.

J Urol. 2016 Jun;195(6):1684-1689. doi: 10.1016/j.juro.2016.01.006. Epub 2016 Jan 14.

20.

Idiographic quality of life assessment before radical cystectomy.

Anderson CB, Rapkin B, Reaves BC, Sun AJ, Morganstern B, Dalbagni G, Donat M, Herr HW, Laudone VP, Bochner BH.

Psychooncology. 2017 Feb;26(2):206-213. doi: 10.1002/pon.4025. Epub 2015 Nov 30.

21.

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.

Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmström PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J.

BJU Int. 2016 Jul;118(1):44-52. doi: 10.1111/bju.13354. Epub 2015 Nov 6.

22.

Genomic Characterization of Upper Tract Urothelial Carcinoma.

Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, Pinciroli P, Rosenberg JE, Dalbagni G, Schultz N, Bajorin DF, Reuter VE, Berger MF, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol. 2015 Dec;68(6):970-7. doi: 10.1016/j.eururo.2015.07.039. Epub 2015 Aug 14.

23.

BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study.

Herr HW, Milan TN, Dalbagni G.

Urol Oncol. 2015 Mar;33(3):108.e1-4. doi: 10.1016/j.urolonc.2014.02.020.

PMID:
25813144
24.

Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.

Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, Coleman JA, Mathew S, Vickers A, Schnorr GC, Feuerstein MA, Rapkin B, Parra RO, Herr HW, Laudone VP.

Eur Urol. 2015 Jun;67(6):1042-1050. doi: 10.1016/j.eururo.2014.11.043. Epub 2014 Dec 8.

25.

External beam radiation therapy for small cell carcinoma of the urinary bladder.

Mattes MD, Kan CC, Dalbagni G, Zelefsky MJ, Kollmeier MA.

Pract Radiat Oncol. 2015 Jan-Feb;5(1):e17-22. doi: 10.1016/j.prro.2014.03.013. Epub 2014 May 28.

PMID:
25413423
26.

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.

Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J.

Eur Urol. 2015 Jan;67(1):74-82. doi: 10.1016/j.eururo.2014.06.040. Epub 2014 Jul 16.

PMID:
25043942
27.

Adherence to surveillance guidelines after radical cystectomy: a population-based analysis.

Ehdaie B, Atoria CL, Lowrance WT, Herr HW, Bochner BH, Donat SM, Dalbagni G, Elkin EB.

Urol Oncol. 2014 Aug;32(6):779-84. doi: 10.1016/j.urolonc.2014.01.024. Epub 2014 Jun 13.

PMID:
24935876
29.

Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings.

Mashni J, Godoy G, Haarer C, Dalbagni G, Reuter VE, Al-Ahmadie H, Bochner BH.

Int Urol Nephrol. 2014 Sep;46(9):1699-705. doi: 10.1007/s11255-014-0719-9. Epub 2014 May 4. Erratum in: Int Urol Nephrol. 2014 Sep;46(9):1707. Ahmadie, Hikmat Al [corrected to Al-Ahmadie, Hikmat].

30.

Contemporary management of penile cancer: greater than 15 year MSKCC experience.

Moses KA, Winer A, Sfakianos JP, Poon SA, Kent M, Bernstein M, Russo P, Dalbagni G.

Can J Urol. 2014 Apr;21(2):7201-6.

31.

Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder.

Spaliviero M, Dalbagni G, Bochner BH, Poon BY, Huang H, Al-Ahmadie HA, Donahue TF, Taylor JM, Meeks JJ, Sjoberg DD, Donat SM, Reuter VE, Herr HW.

J Urol. 2014 Sep;192(3):702-7. doi: 10.1016/j.juro.2014.02.2565. Epub 2014 Mar 3.

32.

Risk factors for the development of parastomal hernia after radical cystectomy.

Donahue TF, Bochner BH, Sfakianos JP, Kent M, Bernstein M, Hilton WM, Cha EK, Yee AM, Dalbagni G, Vargas HA.

J Urol. 2014 Jun;191(6):1708-13. doi: 10.1016/j.juro.2013.12.041. Epub 2013 Dec 30.

33.

The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer.

Meeks JJ, Kern SQ, Dalbagni G, Eastham JA, Sandhu JS.

J Urol. 2014 Jun;191(6):1760-3. doi: 10.1016/j.juro.2013.12.037. Epub 2013 Dec 25.

PMID:
24373801
34.

Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience.

Bazzi WM, Kopp RP, Donahue TF, Bernstein M, Russo P, Bochner BH, Donat SM, Dalbagni G, Herr HW.

Int Sch Res Notices. 2014 Nov 13;2014:702653. doi: 10.1155/2014/702653. eCollection 2014.

35.

Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes.

Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, Shariat SF.

BJU Int. 2014 Jan;113(1):11-23. doi: 10.1111/bju.12121. Review.

36.

Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.

Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, Shariat SF, Maschino A, Vertosick E, Raman JD, Dalbagni G.

BJU Int. 2014 Nov;114(5):674-9. doi: 10.1111/bju.12597. Epub 2014 Oct 3.

37.

Non-squamous cell carcinoma of the penis: single-center, 15-year experience.

Moses KA, Sfakianos JP, Winer A, Bernstein M, Russo P, Dalbagni G.

World J Urol. 2014 Oct;32(5):1347-53. doi: 10.1007/s00345-013-1216-y. Epub 2013 Dec 1.

38.

Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.

Kim PH, Sukhu R, Cordon BH, Sfakianos JP, Sjoberg DD, Hakimi AA, Dalbagni G, Lin O, Herr HW.

BJU Int. 2014 Sep;114(3):354-9. doi: 10.1111/bju.12516. Epub 2014 Feb 14.

39.

The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.

Kim PH, Kent M, Zhao P, Sfakianos JP, Bajorin DF, Bochner BH, Dalbagni G.

World J Urol. 2014 Apr;32(2):453-9. doi: 10.1007/s00345-013-1128-x. Epub 2013 Jul 11.

40.

Radical cystectomy and orthotopic urinary reconstruction in patients with bladder cancer after renal transplantation: clinical outcomes and description of technique.

Moses KA, Bochner BH, Prabharasuth D, Sfakianos JP, Bernstein M, Herr HW, Dalbagni G.

Transplant Proc. 2013 May;45(4):1661-6. doi: 10.1016/j.transproceed.2012.10.050.

41.

Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer.

Sternberg IA, Keren Paz GE, Chen LY, Herr HW, Donat SM, Bochner BH, Dalbagni G.

J Urol. 2013 Oct;190(4):1187-91. doi: 10.1016/j.juro.2013.05.020. Epub 2013 May 13.

PMID:
23680310
42.

Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.

Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW.

J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120. Epub 2013 May 7.

PMID:
23665400
43.

Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.

Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH, Dalbagni G.

BJU Int. 2013 Jun;111(8):E325-30. doi: 10.1111/j.1464-410X.2012.11751.x. Epub 2013 Feb 5.

44.

Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.

Herr HW, Dalbagni G.

BJU Int. 2013 May;111(6):984-7. doi: 10.1111/j.1464-410X.2012.11778.x. Epub 2013 Jan 25.

45.

Management of bladder cancer after renal transplantation.

Prabharasuth D, Moses KA, Bernstein M, Dalbagni G, Herr HW.

Urology. 2013 Apr;81(4):813-9. doi: 10.1016/j.urology.2012.11.035. Epub 2013 Jan 3.

PMID:
23290344
46.

Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.

Sternberg IA, Keren Paz GE, Chen LY, Herr HW, Dalbagni G.

BJU Int. 2013 Jul;112(1):54-9. doi: 10.1111/j.1464-410X.2012.11391.x. Epub 2012 Nov 13.

47.

Preoperative accuracy of diagnostic evaluation of the urachal mass.

Meeks JJ, Herr HW, Bernstein M, Al-Ahmadie HA, Dalbagni G.

J Urol. 2013 Apr;189(4):1260-2. doi: 10.1016/j.juro.2012.10.043. Epub 2012 Oct 23.

PMID:
23089466
48.

Urinary diversion practice patterns among certifying American urologists.

Silberstein JL, Poon SA, Maschino AC, Lowrance WT, Garg T, Herr HW, Donat SM, Dalbagni G, Bochner BH, Sandhu JS.

J Urol. 2013 Mar;189(3):1042-7. doi: 10.1016/j.juro.2012.08.240. Epub 2012 Sep 23.

49.

Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.

Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, Shariat SF, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J.

Eur Urol. 2012 Dec;62(6):1088-96. doi: 10.1016/j.eururo.2012.08.055. Epub 2012 Sep 3. Review.

PMID:
22959049
50.

Epidemiology and risk factors of urothelial bladder cancer.

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y.

Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25. Review.

PMID:
22877502

Supplemental Content

Loading ...
Support Center